-
IMS 2024丨Dr. Juan Li’s Team: Tandem ASCT as a Potentially Effective Strategy for High-Risk MM Patients with Dual Hits of 1q21 Amplification and t(4;14)
From September 25 to 28, 2024, the 21st International Myeloma Society (IMS) Annual Meeting was held in Rio de Janeiro, Brazil. At this prestigious conference, the research led by Dr. Juan Li from The First Affiliated Hospital of Sun Yat-sen University in China was selected for poster presentation. The study suggests that for high-risk multiple…
-
Advancing the Field: Dr. Pei Dong Discusses Groundbreaking Neoadjuvant Therapies for Renal Cancer at CSCO 2024
Surgery is a fundamental treatment for renal cancer, particularly for patients with stage I and II cancers, where surgery can cure the majority of cases and ensure long-term survival. At the 2024 CSCO Annual Meeting, Urology Frontier invited Dr. Pei Dong from Sun Yat-sen University Cancer Center to discuss this year’s key updates in the…
-
CSCO 2024: Dr. Jun Zhu Spearheads China’s Breakthroughs in Anti-Tumor Drug Development
From September 25 to 29, 2024, the 27th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was successfully held in Xiamen. Themed Patient-Centered, Sharing the Future, the conference brought together major research advancements and developments from both domestic and international spheres. Over the past two decades, CSCO has been a continuous leader in…
-
Decoding Gene Silence: Nobel Honors Pioneers of microRNA in Blood Cancer Therapies
The 2024 Nobel Prize in Physiology or Medicine has once again brought the spotlight onto the field of gene regulation. This year, American scientists Victor Ambros and Gary Ruvkun were honored with the prestigious award for their pioneering research on microRNA and its role in post-transcriptional gene regulation. Their groundbreaking discoveries not only opened new…
-
3D Surgery Breakthrough: Dr. Renquan Zhang Talks Innovative Treatment for Elderly Esophageal Cancer Patients
From September 26 to 28, 2024, the China Anti-Cancer Association (CACA) and the CACA Integrative Esophageal Cancer Committee hosted the 2024 CACA Integrative Esophageal Cancer Academic Conference in Hefei. This prestigious event gathered leading experts in the field of esophageal cancer from China and abroad. The topics ranged from cancer prevention, early diagnosis and treatment,…
-
Mao Leads the Way: A New Era in Esophageal Cancer Treatment Commenced at CACA Conference
From September 26 to 28, 2024, the “2024 China Anti-Cancer Association Integrated Esophageal Cancer Academic Conference” was held grandly in Hefei, hosted by the China Anti-Cancer Association (CACA) and the CACA Integrated Esophageal Cancer Committee, with five subcommittees on esophageal cancer joining forces with Anhui Medical University’s First Affiliated Hospital. Alongside, the “16th China Anti-Cancer…
-
Breaking News: ISDE 2024 Spotlights Groundbreaking Predictive Vital Sign Tech for Esophageal Cancer Surgery
From September 22nd to 24th, 2024, the 20th International Society for Diseases of the Esophagus (ISDE) conference was grandly held in Edinburgh, Scotland. A study by Dr. Andrew Seely from the University of Ottawa’s Faculty of Medicine on predictive vital sign monitoring during the perioperative period for esophageal cancer was selected for abstract presentation at…
-
Filipa Fonseca Challenges Traditional EGJ Cancer Classification with Innovative Approach at ISDE 2024
From September 22nd to 24th, 2024, the 20th International Society for Diseases of the Esophagus (ISDE) conference was grandly held in Edinburgh, Scotland. Dr. Filipa Fonseca from the Lisbon Oncology Research Center presented a study on the modified Siewert classification for adenocarcinoma of the esophagogastric junction (EGJ) at the Late-Breaking Oral Abstract session (Abstract No.:…
Connecting Medical Expertise through Media